Targeted drugs of differentiated thyroid cancer: Research advances
10.13220/j.cnki.jipr.2016.04.015
- Author:
Yan-Dong LIU
1
Author Information
1. Guangxi Medical University
- Publication Type:Journal Article
- Keywords:
Antineoplastic agents;
Clinical trails;
Differentiated thyroid cancer;
Targeted therapy;
Thyroid cancer
- From:
Journal of International Pharmaceutical Research
2016;43(4):670-674
- CountryChina
- Language:Chinese
-
Abstract:
Differentiated thyroid cancer is a common endocrine malignancy, and its incidence has increased rapidly in the past 10 years.Although most patients have a good prognosis when treated with traditional methods, it is difficult to achieve satisfactory results for a small part of refractory thyroid cancer. With the understanding of the pathogenesis of thyroid cancer gradually improving to the molecular level, targeting therapy based on mechanisms and molecular targets have become a frontier area in the treatment of refractory thyroid cancer. Up to now,a variety of molecular targets has been found to be closely related to the incidence of thyroid cancer, and their effectiveness and safety has been verified by clinical trials. A number of targeted drugs of refractory thyroid cancer have been found through a method of target-based drug design, and have come into clinical trials or clinical applications. The representative drugs, sorafenib and lenvatinib, were approved for the treatment of refractory differentiated thyroid cancer, which provides a new hope for the treatment of advanced thyroid cancer.
